D. E. Shaw & Co. Inc. Purchases 62,505 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

D. E. Shaw & Co. Inc. lifted its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 32.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 256,083 shares of the company’s stock after acquiring an additional 62,505 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.30% of Atea Pharmaceuticals worth $858,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in AVIR. Bridgeway Capital Management LLC acquired a new position in Atea Pharmaceuticals during the fourth quarter valued at approximately $112,000. Intech Investment Management LLC increased its stake in shares of Atea Pharmaceuticals by 236.0% in the 4th quarter. Intech Investment Management LLC now owns 35,989 shares of the company’s stock valued at $121,000 after purchasing an additional 25,278 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Atea Pharmaceuticals by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 45,391 shares of the company’s stock worth $152,000 after buying an additional 9,865 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of Atea Pharmaceuticals during the 4th quarter worth $168,000. Finally, Bank of America Corp DE lifted its position in shares of Atea Pharmaceuticals by 23.3% during the 4th quarter. Bank of America Corp DE now owns 73,441 shares of the company’s stock worth $246,000 after buying an additional 13,902 shares during the last quarter. Institutional investors own 86.67% of the company’s stock.

Atea Pharmaceuticals Stock Up 1.8%

Shares of AVIR stock opened at $2.90 on Friday. Atea Pharmaceuticals, Inc. has a twelve month low of $2.46 and a twelve month high of $4.15. The stock’s fifty day simple moving average is $2.88 and its 200 day simple moving average is $3.08. The firm has a market capitalization of $248.18 million, a P/E ratio of -1.40 and a beta of 0.17.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.16. As a group, equities research analysts expect that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on AVIR shares. Morgan Stanley decreased their target price on Atea Pharmaceuticals from $6.20 to $6.00 and set an “equal weight” rating on the stock in a research report on Friday, April 11th. Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Finally, William Blair reissued an “outperform” rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.